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A b s t r a c t    
 
 
Dietary supplementation of nicotinamide adenine dinucleotide (NAD+) precursors has been suggested as a treatment for non-alcoholic fatty liver disease and obesity. In the liver, 
NAD+ is primarily generated by nicotinamide phosphoribosyltransferase (NAMPT), and hepatic levels of NAMPT and NAD+ have been reported to be dependent on age and 
body composition. The aim of the present study was to identify time course-dependent changes in hepatic NAD content and NAD+ salvage capacity in mice challenged with 
a high-fat diet (HFD). We fed 7-week-old C57BL/6JBomTac male mice either regular chow or a 60% HFD for 6, 12, 24, and 48 weeks, and we evaluated time course-
dependent changes in whole body metabolism, liver steatosis, and abundance of hepatic NAD-associated metabolites and enzymes. Mice fed a 60% HFD rapidly accumulated 
fat and hepatic triglycerides with associated changes in respiratory exchange ratio (RER) and a disruption of the circadian feeding pattern. The HFD did not alter hepatic NAD+ 
levels, but caused a decrease in NADP+ and NADPH levels. Decreased NADP+ content was not accompanied by alterations in NAD kinase (NADK) abundance in HFD-
fed mice, but NADK levels increased with age regardless of diet. NAMPT protein abundance did not change with age or diet. HFD consumption caused a severe decrease 
in protein lysine malonylation after six weeks, which persisted throughout the experiment. This decrease was not associated with changes in SIRT5 abundance. In 
conclusion, hepatic NAD+ salvage capacity is resistant to long-term HFD feeding, and hepatic lipid accumulation does not compromise the hepatic NAD+ pool in HFD-





In non-alcoholic fatty liver disease (NAFLD) lipids accumulate in the liver 
without significant alcohol consumption or viral infection (Angulo, 2002). 
Reported prevalence varies both with geographic location and detection 
method applied for diagnosis. Prevalence in the adult European populations 
ranges from 20% to 31% (Blachier et al., 2013). NAFLD development 
associates with  obesity  and type 2 diabetes, where prevalence is reported to 
be as high as 70% (Lazo and Clark, 2008). As the number of obese people is 
increasing worldwide, it is estimated that the number of people with NAFLD 
will follow (Loomba and Sanyal, 2013). While hepatic steatosis has been 
described as benign and non-progressive (Yilmaz, 2012), several studies 
have reported progression of NAFLD to non- alcoholic steatohepatitis 
(NASH) and fibrosis  (McPherson et al., 2015; Pais et al., 2013; Wong et 
al., 2010). NASH can further prog- ress to cirrhosis and liver cancer 
(Ekstedt et al., 2006). Simple steatosis can  be  improved  through  lifestyle  
intervention  (Shah et al., 2009), but boosting levels of nicotinamide adenine 
dinucle- 
otide  (NAD+)  has  also  been  suggested  as  a  possible  treatment 
strategy (Gariani et al., 2016). 
In the liver, NAD+ can be generated from tryptophan or nicotinic acid 
(Fukuwatari and Shibata, 2013), but the majority of NAD+  is generated 
from nicotinamide, which is converted to nicotinamide mononucleotide 
(NMN) in the rate-limiting step mediated by nicotinamide 
phosphoribosyltransferase (NAMPT), and into NAD+ by nicotinamide  
mononucleotide  adenylyltransferases (NMNAT1- 
3) (Verdin, 2015). In rodents, several studies have demonstrated decreased 
NAD+ levels and/or NAMPT abundance in the liver following high-fat diet 
(HFD) feeding (Choi et al., 2013; Gariani et al., 2016; Uddin et al., 2017; 
Wang et al., 2017; Yoshino et al., 2011; Zhang et al., 2014; Zhou et al., 
2016). NMN can attenuate HFD-induced phenotypes and restore NAD+ levels 
(Yoshino et al., 2011). In several other animal models for obesity, dietary 
supple- mentation with nicotinamide riboside (NR), another NAD+ pre- 
cursor, prevented hepatic lipid accumulation, enhanced insulin sensitivity, 
glucose tolerance, and decreased fat mass accumulation (Canto et al., 2012; 
Gariani et al., 2016; Trammell et al., 2016). Additionally, supplementation 
with NAD+ precursors has been shown to have substantial anti-aging effects in 
rodents (Mills et al., 2016; Zhang et al., 2016). NAD+ precursor supplementation 
is thought to reverse HFD-induced hepatic lipid accumulation through 
activation of the sirtuins, a family of deacylase proteins (i.e., SIRT1-7). 
Sirtuins cleave NAD+ to nicotinamide and O-acetyl- ADP-ribose and activity 
can be enhanced by increasing NAD+ levels (Wood et al., 2004). Sirtuins 
modulate a number of target proteins that regulate glucose and lipid metabolism, 
mitochondrial function, and mitochondrial biogenesis (Giblin et al., 2014). 
Decreased he- patic expression of SIRT1, SIRT3, SIRT5, and SIRT6 has been 
reported in patients with NAFLD (Wu et al., 2014), while liver-specific 
knockout of SIRT1 and SIRT6 in mice results in hepatic lipid accu- mulation 
(Kim et al., 2010; Purushotham et al., 2009). Consistently, overexpression of 
SIRT1 protects against HFD-induced obesity (Pfluger et al., 2008), and 
increasing the hepatic NAD pool by in- hibition of the NAD+-consuming 
enzymes poly-ADP ribose poly- merases (PARPs) decreases weight gain and 
hepatic steatosis development by a SIRT1-dependent mechanism in high-fat 
high- sucrose-fed mice  (Gariani et  al., 2017). Hence,  sufficient sirtuin activity 
appears  important for  prevention  of hepatic lipid accu- mulation. It is not 
known if impaired NAD+ synthesis or increased NAD+ consumption is 
responsible for diet-induced impairments in sirtuin activity. Furthermore, it is 
not known if insufficient NAD+ levels and sirtuin activity precede steatosis 
development in obese rodents, or if NAD+ depletion arises following hepatic 
lipid accu- mulation. In this study, we aimed to determine the HFD-induced 
and time course-dependent changes in hepatic NAD and NAD+ salvage systems. 
 
2. Materials and methods 
 
2.1. Chemicals and reagents 
 
Unless otherwise noted, all chemicals and reagents were pur- chased from 
Sigma Aldrich (Germany). 
 
2.2. Mouse experiments 
 
  
Mouse experiments were performed in accordance with the European 
directive 2010/63/EU of the European Parliament and of the Council for the 
protection of animals used for scientific pur- poses. Ethical approval was 
given by the Danish Animal Experi- ments Inspectorate (#2012-15-2934-
307). 
 
2.3. High-fat diet time course experiment 
 
Sixty-eight male C57BL/6JBomTac (Taconic, Denmark) mice were 
acquired at 5 weeks of age and were acclimatized to the an- imal facility at 
University of Copenhagen for 2 weeks. The C57BL/6JBomTac strain was 
chosen, as these mice do not contain a re- ported mutation in the 
nicotinamide nucleotide transhydrogenase (NNT) gene known to be present 
in C57BL/6J mice (Toye et al., 2005). Mice were single-housed  and  
distributed  into  eight groups, matched by lean body mass determined by 
NMR scanning (EchoMRI 4-1, EchoMRI, TX, USA). Half of the groups 
were fed a standard “Chow” diet (Altromin 1319, Brogaarden, Denmark) con- 
taining 13.7 kJ/g, and the other half was fed a 60% HFD containing 
21.8 kJ/g (D12492, Research Diets, NJ, USA). Mice were housed in 
temperature-controlled conditions (22 ± 1 oC) with a 12-h light/ dark cycle 
(from 6 AM to 6 PM) and feed and water ad libitum. NMR scanning was used 
to determine fat mass accumulation and body composition throughout the 
experiment. For each diet, separate groups were sacrificed at 6, 12, 24, and 
48 weeks of treatment after being subjected to one week of metabolic 
chamber measurements. Mice were given 2 days of recovery after the 
metabolic chamber measurements before being sacrificed from 1 PM to 
5 PM. Mice were sedated using isoflurane and sacrificed by cardiac 
puncture. The liver was removed and part of the lobus dexter, lobus sinister, 
and lobus caudatus were fixed in 4% PFA solution. Another part of the lobus 
dexter and lobus sinister were snap-frozen whole  in liquid nitrogen for Oil-
Red O staining, and the remaining part of the liver was quickly cut into 
smaller pieces and snap-frozen in liquid nitrogen. Samples were stored at 
-80 oC and pulverized in liquid nitrogen prior to analysis. 
 
2.4. Metabolic chamber measurements 
 
Prior to the measurements, mice were placed in habituation cages for 
6 days, to adapt to the novel environment. Immediately before being 
transferred to the habituation cages, mice were fasted for 6 h from 8 AM (2 
h in light phase), and blood glucose levels were measured from the tail vein 
(Contour Classic glucose meter; Ascensia Diabetes Care Holdings, 
Switzerland). Following habitua- tion, mice were placed in the metabolic 
chambers for one week (TSE LabMaster, TSE Systems, Germany). Oxygen 
consumption, CO2 production, food intake, and water intake were 
evaluated every 
20 min. Data from 4 days of measurement were used to calculate average 
values for each time point for each mouse. These values were then used 
to calculate the average values for each diet/age group for each time point 
throughout the light and dark phase. 
 
2.5. Histology and oil-red o staining 
 
Frozen liver tissues were cryo-sectioned (6 µm) and stained with 
Oil-red O for quantitative and qualitative lipid analysis. Liver sections were 
fixed in 4% PFA, embedded in paraffin, cut in 6 µm slices and stained with 
hematoxylin/eosin (H&E) (Gebhardt, 1992). For visualization, a Leica 
DM5000B microscope (Germany) was used. 
 
2.6. NAD+, NADP+, NADH, and NADPH measurement 
 
NAD+ and NADH levels were determined using an enzymatic cycling 
assay (Graeff and Lee, 2002). Livers were processed  by lysing 10e20 mg of 
pulverized tissue in 400 mL of either 0.6 M perchloric acid (for NAD+) or 
0.1 M NaOH (for NADH) with a Tis- suelyser II (Qiagen, Hilden, Germany). 
The NADH extract was incubated at 70 oC for 10 min, and both fractions 
were centrifuged for 3 min at 13.000 g. The supernatants were transferred 
to new 
tubes. The NAD+ extracts were diluted 1:1600 in 100 mM Na2HPO4 
buffer (pH 8) and the NADH extracts were diluted in 1:500 in 10 mM 
Tris (pH 6). 100 mL of the diluted extracts were pipetted into a white 96-well 
plate, and were added 100 mL reaction mix, con- taining 100 mM Na2HPO4, 
10 mM flavinmononucleotide, 2% ethanol,90 U/mL alcohol dehydrogenase, 
130 mU/mL diaphorase, 2.5 mg/mL resazurin and 10 mM nicotinamide. 
Fluorescence increase (Ex 540 nm/Em 580) was measured over 30 min 
and content of each metabolite was calculated from a standard curve and 
normalized to tissue weight. NADP+ and NADPH levels were determined 
from the same extracts, but with a reaction mix containing 100 mM 
Na2HPO4, 10 mM flavinmononucleotide, 1.2 U/mL glucose 6- phosphate 
dehydrogenase, 10 mM glucose 6-phosphate, 130 mU/ mL diaphorase, 2.5 




Chemicals and reagents: All chemicals and reagents used were of liquid 
chromatography-mass spectrometry (LC-MS) grade unless otherwise stated. 
D5-tryptophan, methanol, water, acetonitrile, 2- propanol, formic acid, 
ammonium hydroxide were purchased from Sigma Aldrich (Denmark) and 
hexakis(2,2-difluoroethoxy) phosphazene from Apollo Scientific (UK). 
Metabolites extraction: Samples were randomized for processing and 
blanks (empty microcentrifuge tubes)  were included  in the preparation. 
Tissues were prepared for metabolomics by weighing off approximately 50 mg 
of pulverized liver (exact weight was recorded). Each sample was added 0.5 
mL cold 50% methanol in water (containing 0.008 mg/mL D5-tryptophan for 
normalization) and were homogenized using a Tissuelyser II with methanol- 
washed beads. Each sample was added 0.5 mL chloroform (con- taining 
0.013 mg/mL D35 stearic acid for normalization). Samples were vortexed and 
incubated for 30 min at 1 oC at highest speed on a Thermomixer Comfort 
(Eppendorf, Germany). Samples were centrifuged at 0 oC for 10 min at 1,500 
g. Methanol/water fraction was separated from the chloroform one into new 
pre-chilled tubes. Methanol/water extract was centrifuged at 0 oC for 10 min 
at 13,400 g. Supernatants were transferred to new tubes and after short 
vortexing 10 mL of  each sample was collected to one pre- chilled 
microcentrifuge  tube, creating a Quality Control sample (QC). Finally, all 
samples were stored at -80 oC until LC-MS analysis. 
LC-MS metabolic p r o f i l i n g : Methanol/water extracts, QC samples and 
blanks were defrosted on ice, vortexed and set in a pre-chilled LC-MS vial 
(Verex Vial, mVial i3 Qsert, Phenomenex) with a screw- cap (Verex Cert + 
MSQ Cap, Phenomenex). Leftover samples were stored at -80 oC. Metabolic 
profiling was conducted using a LC-MS system: Samples were maintained at 4 
oC throughout the analysis. QC samples and blanks were injected after each 
5th sample. Chromatographic separation was performed using UHPLC Dionex 
Ultimate 3000 (Thermo Scientific, Germany) with Luna Polar C18 column (1.6 
mm, 2.1 x 100 mm, Phenomenex, USA) with EVO C18 guard column (sub-
2mm, 2.1 mm, Phenomenex, USA) kept at 40 oC. Solvent A and B were 0.1% 
formic acid in acetonitrile and 0.1% formic acid with 5 mM ammonium 
hydroxide in LC-MS grade water, respectively. A flow rate of 0.3 mL/min was 
applied with a gradient elution profile: 95% B 0e1 min, 95%e5% B 1.0e10.0 min, 
5% B 10.0e12.0 min, 5e95% B 12.0e12.5 min, 95% B 12.5-14-5 min 
(equilibration step). LC was coupled with QToF Impact II mass spectrometer 
(Bruker Daltonics, Germany) operating in electro- spray ionization. Samples 
were analyzed in positive and negative mode. 5 mL of the extract was injected 
in positive mode and 10 mL in the negative mode. Line and profile MS spectra 
were acquired in the mass range 50e1000 mass to charge ratio (m/z) at 2.00 Hz 
spectra rate using the source settings for positive mode: absolute threshold 50 
cts per 1000 sum, End Plate Offset 500 V, Capillary 4500 V, Nebulizer 2.0 
Bar, Dry Gas 10.0 l/min, Dry Temperature 220 oC; Transfer: Funnel 1RF 150.0 
Vpp, Funnel 2FR 200.0 Vpp, isCID Eergy 
0.0 eV, Hexapole RF 50.0Vpp; Quadrupole: Ion Enegry 4.0 eV, Low Mass 
100.0 m/z; Collision Cell: Collision Energy 7.0 eV, Transfer Time 65.0 ms, 
Collision RF 650.0 Vpp, Pre Pulse Storage 5.0 ms. In negative mode Capillary 
voltage was set to 3000 and other pa- rameters were identical as described 
above for both modes. MS spectra were divided into 3 segments: pre-
analysis 0e0.1 min, calibration 0.1e0.5 min, analysis 0.5e14.5 min. External 
and inter- nal calibration was based on sodium formate clusters in 2-propanol 
with Zoom of 1.0% and HPC mode. Additionally, lock-mass cali- bration 
based on hexakis(2,2-difluoroethoxy)phosphazene in 2- propanol (0.1 
mg/mL) throughout the whole scan was applied. Targeted MSMS analysis 




was performed at the same LC-MS settings as the MS scans with additional 
collision energy set to 20 and scan width 1.0 m/z for both negative and 
positive mode. 
LC-MS data analysis: Raw data from the positive and negative mode 
were automatically calibrated according to the sodium- clusters and lock-
mass shifts throughout the analysis, using the Compass Data Analysis 4.3 
(Bruker Daltonics, Germany). Files were converted to NetCDF format through 
the Bruker software and metabolic features were extracted using R-based 
(Team, 2013) XCMS (Smith et al., 2006), following CAMERA analysis (Kuhl 
et al., 2012). Data were normalized according to the internal standard 
abundance and samples weight. Statistical analysis was performed using 
online analytical tools within MetaboAnalyst 3.0 (Xia and Wishart, 2002). 
CAMERA-generated buckets  were  log- transformed and Pareto-scaled. 
Non-informative variables were removed based on their standard deviation. 
Initially Principal Component Analysis was made to visualize the clustering 
of the samples, QCs and blanks in search for potential contaminations, 
machine drifts and outliers. Two-factor independent study using 2- way 
ANOVA with False Discovery Rate (FDR) analysis was used to select 
significantly different metabolic features. Initially, signifi- cantly different 
metabolic features (p < 0.05, FDR corrected) were matched with metabolites 
in Human Metabolome Database (Wishart et al., 2013) and Metlin Database 
(Smith et al., 2005) ac- cording to the mass to charge ratio. Provided at the 
databases ID numbers for metabolites in Kyoto Encyclopedia of Genes and 
Ge- nomes (KEGG) (Kanehisa et al., 2017) were used to perform a batch 
search in relation to affected pathways. Following, MSMS profile was 
acquired for metabolites from significantly affected metabolic pathways 
and matched to the MSMS from databases. 
 
2.8. Western blot analyses 
 
For Western blot analyses, approximately 20 mg pulverized tissue was 
homogenized in 500 mL lysis buffer (pH 7.4, 10% glycerol, 1% IGEPAL, 50 
mM Hepes, 150 mM NaCl, 10 mM NaF, 1 mM EDTA, 
1 mM EGTA, 20 mM sodium pyrophosphate, 2 mM sodium ortho- 
vanadate, 1 mM sodium-pyrophosphate, 5 mM nicotinamide, 4 mM Thiamet 
G and protease inhibitors (S8820, SigmaFast)) using a Tissuelyser II 
(Qiagen, Germany), 2 x 30 s of 30 Hz. Lysates were incubated end-over-
end for 45 min at 4 oC, and were centrifuged for 10 min at 16.000 g at 4 
oC. Protein concentration was deter- mined using the Bicinchoninic Acid 
Assay (23227, ThermoFisher Scientific, MA, USA). 20 mg of protein lysate 
was loaded on acryl- amide SDS-page gels and subject to electrophoresis, 
together with Precision Plus Protein All Blue Standards and Precision Plus 
Protein Dual Color Standards (Bio-Rad, CA, USA) to determine band size. 
Proteins were then transferred to polyvinyl difluoride membrane (PVDF, 
#Ipvh00010, Millipore, Germany) by semi-dry transfer and subjected to 
immunoblotting. Membranes were incubated ac- cording to the 
manufacturer's instructions with the following an- tibodies: NAMPT (372A, 
Bethyl lab, TX, USA), NMNAT1 (45548, Abcam, UK), NMNAT3 (116288, 
Abcam), NRK1 (398852, Santa Cruz, TX, USA), AFMID (19522-1-AP, 
Proteintech, IL, USA), NAPRT1 (123023, Abcam), NADK (A304-993A, 
Bethyl Labs), SIRT1 (07-131, 
Millipore), SIRT3 (5490, Cell Signaling, MA, USA), SIRT5 (8782, Cell 
signaling), SIRT6 (12486, Cell Signaling), PARP1 (9542, Cell Signaling), 
Acetyl Lysine (9441s, Cell Signaling), Malonyl Lysine (14942, Cell 
Signaling). Following wash in TBS-T, membranes were incubated with HRP-
conjugated antibodies, anti-rabbit (170-6515, Biorad, CA, USA) or anti-mouse 
(170-6516, Biorad) according to the manufacturer's instructions. Membranes 
were developed using a Chemidoc XRS+ (Biorad) using Lumina Forte 
Western HRP Substrate (Millipore). Bands were quantified using the Image 
Lab software (Bio-Rad) and band intensity was normalized to the band 
intensity of an internal control of mixed liver samples loaded twice on all gels. 
 
2.9. Quantitative real-time PCR 
 
Total RNA of liver tissue was extracted by TRIzol® Reagent (Life 
Technologies) according to manufacturer's protocol. 1 mg of total RNA 
was transcribed into cDNA by M-MLV Reverse Transcriptase (#28025013, 
Invitrogen). Quantitative PCR analyses were per- formed using the qPCR 
Master Mix Plus Low ROX (Eurogentec) or Absolute qPCR SYBR Green Low 
ROX Mix (Thermo Scientific) and the Applied Biosystems 7500 Real Time PCR 
System. Nampt mRNA expression (forward: 50 - GAT GGT CTG GAA TAC AAG 
TTA CAT GAC T-3’; reverse: 50 -ATG AGC AGA TGC CCC TAT GC-30, probe: 
50-AGG 
AGT CTC TTC GCA AGA GAC TGC T-30) was normalized to Cyclo- phillin 
(forward: 50- ATG TGG TTT TCG GCA AAG TT-3’; reverse: 50- TGA CAT CCT 
TCA GTG GCT TG-30) 
 
2.10. Statistical analysis 
 
Data are presented as mean ± SEM. Data were analyzed using 2- way analysis 
of variance (ANOVA) with Sidak's multiple compari- son test post hoc. All 
statistical analysis was performed using Graphpad Prism 6 (Graphpad Software, 
CA, USA). Statistical sig- nificance  was  defined  as  p  < 0.05.  */**  indicate  
effects  of  diet, 





3.1. Six weeks of high-fat diet causes fat mass accumulation, 
decreased RER, and altered feeding behavior 
 
We first investigated how HFD feeding affects fat mass accu- mulation 
and whole-body metabolism over time. While no change was observed in 
absolute weight between chow- and HFD-fed mice until week 36 (Fig. 1A, p < 
0.01, n = 8), there was a marked differ- ence in body composition early after 
HFD exposure. In HFD-fed mice, weight gain was due to rapid fat mass 
accumulation, which kept increasing throughout the study (Fig. 1B, p < 0.01, n = 
7e8). In contrast, during the first 12 weeks chow-fed mice showed a larger 
increase in lean mass gain compared to the HFD group, which persisted 
throughout the study (Fig. 1C, p < 0.01, n = 7e8). 6 weeks of HFD feeding caused 
major changes in RER and feed intake pat- terns. Throughout the study, a 
circadian pattern in RER was observed in chow-fed mice, with a large increase 
in RER during the dark phase, which became smaller with age (Fig. 1D). The 
HFD-fed mice had only minor circadian RER oscillations at all 4 time-points. 
Daily food intake patterns were only different between diets at 6 and 12 
weeks, where a significant interaction was observed be- tween diet and time 
of day (Fig. 1E). At the first two time-points, chow-fed mice were primarily 
eating in the dark phase, while HFD-fed mice had a continuous food intake 
throughout the dark and light phase. The chow group's feeding pattern 
became more irregular after 24 weeks  (diet x  feeding time interaction  effect, 
p = 0.07), and after 48 weeks mice consumed an equal amount of calories 
throughout dark and light phase regardless of diet. Hence, HFD consumption 
caused major changes in whole-body meta- bolism within the first 6 weeks of 
the study. Fasting blood glucose levels were not affected by age, and did not 
differ between chow- and HFD-fed mice (Fig. 1F). Thus, HFD consumption 
caused major changes in whole-body metabolism in C57BL6/JBomTac mice 
within the first 6 weeks of HFD feeding, but glycemic control did not appear 
to be affected by the dietary intervention. 
 
3.2. High-fat diet feeding causes progressive accumulation 
of hepatic triglycerides 
 
To assess if liver steatosis development accompanied the rapidly induced 
HFD phenotype, we measured hepatic triglyceride content by oil-red o 
staining (Fig. 2A). HFD feeding caused a significant increase in hepatic 
lipid content after 6 weeks, which became more severe with time (Fig. 2C, p < 
0.01, n = 3). The presence of steatosis in the HFD-fed groups was also 
confirmed by H&E staining, which showed visible steatosis after 24 weeks 
(Fig. 2B). After 48 weeks, chow-fed mice also had an increased content of 
lipids compared to earlier time points (Fig. 2C, p < 0.01, n = 3). Therefore, 
while HFD causes rapid accumulation of hepatic lipids, this did not progress 
to macrovesicular steatosis until after 24 weeks. Hence, whole-body fat 
mass accumulation preceded hepatic macrovesicular steatosis. 
  
  
3.3. High-fat diet feeding decreases hepatic NADP(H) content 
but not NAD+ levels 
 
To assess if hepatic NAD levels were affected by HFD-induced hepatic 
lipid accumulation, we measured hepatic NAD+, NADH, NADP+, and 
NADPH content at all 4 time-points. Hepatic NAD+ levels were not 
significantly  altered by HFD feeding, but were decreased in the 48-week 
groups compared to the 24-week groups (Fig. 3A, P < 0.05, n =7-9). NADH 
levels were not significantly altered,  though  we   observed   borderline   
effects   of   both   age (p ¼ 0.06) and diet (p ¼ 0.09) (Fig. 3B, n = 7-9). In 
contrast, we observed a small, but consistent decrease in NADP levels in all 
the HFD groups (Fig. 3C, p < 0.01, n = 7-9). The same was observed for 
NADPH (Fig. 3D, p < 0.01, n = 7-9). LCMS analysis confirmed the HFD-
induced decrease in NADP+ (data not shown) but no other terms associated 
with NAD metabolism were altered with age or diet. Enrichment analysis 
of the metabolomics data suggested changes in purine metabolism. As 
generation of NAD+ and NADP requires ATP (Canto et al., 2015), we 
quantified levels of ATP- associated metabolites in the liver samples. 
Hepatic ATP levels increased during the first 24 weeks of the experiment 
and decreased after 48 weeks regardless of diet (Fig. 3E, p < 0.01). Levels 
of adenine, a pre-cursor of ATP (Dudzinska et al., 2010), decreased slightly 
with age (Fig. 3F, p < 0.05), and levels of hypoxanthine, a deamination 
product of AMP, likewise decreased from 6 to 24 weeks (Fig. 3G, p < 
0.01). This indicates decreased purine catabo- lism with age (Maiuolo et 
al., 2016) that may have caused the in- crease in hepatic ATP levels. No 
change was observed for AMP levels with age, but AMP levels were 
increased in HFD-fed groups (Fig. 3H). Adenosine levels oscillated slightly 
with age (Fig. 3I, main effect of age p < 0.05), with a borderline increases 
after 12 weeks (p = 0.07) which decreased after 48 weeks (p = 0.07). We 
observed no enrichment for terms associated with the pentose phosphate 
pathways with age or diet (data not shown), suggesting no change in levels 
or synthesis of phosphoribosyl pyrophosphate, the co- substrate of 
NAMPT. However, our analysis revealed a significant decline in 
nicotinamide content from 6 to 12 weeks regardless of diet (Fig. 3I, p < 
0.05), which persisted throughout the experiment. While there was no 
significant difference between the 6-week and 48-week groups, we still 
observed a tendency towards a decrease 







Fig. 1. High-fat diet feeding causes mice to rapidly accumulate fat mass, decrease RER and affect their circadian feeding pattern. Mice were fed a 60% HFD for 48 weeks. Throughout the experiment, (A) total 
body weight, (B) fat mass, and (C) lean mass were measured. Prior to each sacrifice point, mice were monitored in metabolic chambers. Graphs show pooled averages for the first 4 days of measurements. 
Grey area indicates dark phase and white area indicates light phase. Graphs show (D) average RER and (E) Food intake in kJ, after 6, 12, 24, and 48 weeks of either chow (black) or HFD consumption (red). 
*/** indicate effects of diet, p < 0.5/0.01, respectively. #/## indicate effects of age, p < 0.05/0.01, respectively. n = 7e8 per group per time point. 
 
(p = 0.08). This could indicate a decrease in hepatic NAD turnover or an 
improvement of NAD+ salvage capability. Thus, the LCMS analysis 
demonstrated only minor changes in hepatic NAD meta- bolism with age 
and HFD feeding in C57BL/6JBomTac mice. 
 
 
3.4. Abundance of NAD+ consuming or -synthesizing enzymes is 
resistant to HFD feeding 
 
Aging in mice has been reported to cause a shift in hepatic NAD+ salvage 
pathways, with a decreased abundance of NAMPT and an increased 
abundance of NMNATs and enzymes involved with de novo synthesis of 
NAD (Zhou et al., 2016). As HFD feeding has also 
been  reported  to  affect  mRNA  levels  of  NAD+  salvage  pathway 
enzymes (Drew et al., 2016), we investigated if protein abundance of these 
enzymes were altered by age and/or diet. NAMPT protein 
abundance was not affected by age or diet (Fig. 4A), but Nampt mRNA 
levels increased with age regardless of diet, indicating that more Nampt 
mRNA is required to maintain NAMPT protein abun- dance (Fig. 4B, p < 0.01, 
n = 8). NMNAT1 abundance increased after 
24 weeks  and  48  weeks  regardless  of  diet  (Fig.  4C,  p < 0.01, n = 7-9), 
but was significantly increased in HFD-fed compared to chow-fed animals 
(p < 0.05). In contrast, NMNAT3 abundance was decreased in  HFD-fed  
animals  (Fig.  4D,  main  effect  p < 0.05, n = 7-9) but did not change with 
age. This could indicate an increased demand for NAD+ in the nucleus where 
NMNAT1 is localized, with a corresponding decreased demand for NAD+ in 
the mitochondria where NMNAT3 is localized. Nicotinamide riboside kinase 
1 (NRK1) abundance  was increased after 48  weeks compared to the 6-week 
time-point (Fig. 4E, p < 0.01, n = 7-9) but 





Fig. 2.  High-fat diet feeding causes hepatic lipid accumulation. Livers were oil-red o stained to evaluate hepatic lipid accumulation. (A) Representative images for each time-point were selected for the figure. 
(B) To assess hepatic steatosis development, livers were subject to H&E staining. Representative images from each time point are displayed. (C) Staining intensity of the oil-red O sections was used to quantify 
hepatic lipid content (n = 3 per group per time point). */** indicate effects of diet, p < 0.5/0.01, respectively. #/## indicate effects of age, p < 0.05/0.01, respectively. 
 
an essential enzyme in the generation of NAD from tryptophan, was not 
significantly affected by either diet or age (Fig. 4F). NAPRT1, which 
converts nicotinic acid to nicotinic acid mononucleotide was not altered by 
diet or age (Fig. 4G, n = 7-9). As HFD caused a decrease  in  NADP(H) 
levels, we  measured abundance of NAD kinase 
(NADK) (Verdin, 2015). NADK levels were not affected by HFD, but increased 
with age in both diet groups (Fig. 4H, p < 0.01, n = 7-9). While the abundance 
of NAD+ synthesizing enzymes were not dramatically affected by HFD 
feeding, we hypothesized that NAD+ consuming enzymes could be affected. 








Fig. 3. High-fat diet feeding decreased hepatic NADP and NADPH levels without affecting NAD content. To investigate how high-fat diet feeding affects the hepatic NAD pool, we measured liver (A) NAD
+ 
levels and (B) NADH levels. We also measured (C) NADP
+ 
levels and (F) NADPH levels. Using MSMS we measured abundance of (D) ATP, (E) Adenine, (F) Hypoxanthine, (G) AMP, (G) Adenosine, and (I) 
nicotinamide. */** indicate effects of diet, p < 0.5/0.01, respectively. #/## indicate effects of age, p < 0.05/0.01, respectively. n = 7-9 
per group per time point. 
 
affect protein abundance of SIRT1, SIRT3, SIRT5, or SIRT6 (Fig. 4IeL). In 
contrast, PARP1 abundance was slightly elevated in HFD-fed mice (Fig. 
4M, p < 0.05, n = 7-9). To evaluate if endogenous sir- tuin activity was 
altered, we determined two sirtuin-regulated post-translational modifications 
of lysine residues, acetylation (Fig. 5A) and malonylation (Fig. 5B) (Du et 
al., 2011; Giblin et al., 2014). A tendency towards decreased acetylation 
following HFD feeding was observed (Fig. 5A, p = 0.09), as was a tendency 
towards decreased lysine acetylation with age (Fig. 5A, p = 0.05). In contrast, 
HFD-feeding resulted in decreased global lysine malonylation of multiple 
bands from 6 weeks of HFD-feeding (Fig. 5B, p < 0.05). This change persisted 
throughout the experiment. Hence, while HFD 
feeding only cause minor changes to NAD-associated metabolites and 




The relationship between NAMPT/NAD+ levels and NAFLD development 
is incompletely known. Data obtained from humans are inconclusive with 
one study reporting decreased NAMPT mRNA expression in the liver of 
NAFLD patients compared to healthy controls (Dahl et al., 2010), whereas 










consuming enzymes. To investigate how HFD- feeding and aging 
affected the proteins involved in NAD
+ 
salvage, we measured hepatic (A) NAMPT protein abundance, (B) Nampt mRNA levels, (C) NMNAT1 protein abun- dance, (D) NMNAT3 protein abundance, 
(E) NRK1 protein abundance, (F) AFMID protein abundance, (G) NAPRT1 protein abundance, and (H) NADK protein abundance. We also measured the abundance of (I) SIRT1, (J) SIRT3, (K) SIRT5, (L) 









Fig. 5. High-fat diet feeding causes decreased global lysine malonylation. To evaluate how sirtuin-regulated lysine modifications were affected by HFD consumption and aging, (A) global lysine acetylation 
and (B) global lysine-malonylation were measured by Western blot analyses. Lane intensity was quantified and used to determine effects of age or diet on lysine acetyl/malonylation. */** indicate effects of 
diet, p < 0.5/0.01, respectively. #/## indicate effects of age, p < 0.05/0.01, respectively. n = 7-9 per group per time point. 
 
compared to lean controls (Auguet et al., 2013). To understand how obesity 
and hepatic lipid accumulation affect NAD metabolism and the hepatic 
NAD+  salvage pathway, we performed a HFD time course study for 48 
weeks in C57BL/6JBomTac mice. While the decreased lean mass in the 
HFD-fed groups was surprising, the 
increased fat mass accumulation, changes in RER, and altered feeding 
behavior are well-characterized effects of HFD feeding (Kohsaka et al., 
2007; Williams et al., 2014). We found that mice accumulated a large 
amount of fat mass and hepatic triglycerides, which was associated with 
decreased hepatic content of NADP+ and NADPH as previously reported 
(Trammell et al., 2016). The decreased NADP+ levels were not 
accompanied by a decrease in NADK abundance. However, NADK 
abundance increased with age regardless of diet, which may reflect higher 
demands for NADP with age. 
HFD consumption did not severely affect hepatic NAD+ levels, 
the abundance of NAD+ producing enzymes, or sirtuin protein levels. This is 
in contrast to several previous studies, which have described decreased 
NAMPT and/or NAD+ levels in the liver of obese rodents (Choi et al., 2013; 
Gariani et al., 2016; Uddin et al., 2017; Wang et al., 2017; Yoshino et al., 
2011; Zhang et al., 2014; Zhou et al., 2016). Moreover,  we  have  previously  
reported elevated hepatic NAD+ levels in HFD-fed mice (Penke et al., 2015), 
and levels of Nampt mRNA were increased and NAD+ unaltered in mice fed 
a 60% HFD from 3 days to 16 weeks (Drew et al., 2016). While most of the 
studies compare HFD-fed animals to animals fed an unmatched chow diet, 
two studies used a matched low-fat diet to ensure comparable micronutrient 
composition of the diets (Wang et al., 2017; Zhang et al., 2014). Thus, one 
explanation for the discrepancies in the reported responses to HFD feeding 
may be related to the level of NAD+ precursors in the diets. However, levels 
of NAD+ precursors in the diets used in the present study do not appear to 
explain the inconsistent findings. While none of the diets contained 
nicotinamide, nicotinic acid content was 63 mg/g diet in chow vs. 30 mg/g 
diet in the HFD. Moreover, tryptophan levels were 
2.9 mg/g diet in the chow diet, but tryptophan content of the HFD was not 
reported by the manufacturer. Tryptophan content in the HFD can, however, 
be estimated to 3.2 mg/g, as this diet contained 
258.4 g  casein pr.  kg,  with  an  estimated  tryptophan  content of 
12.5 mg/g protein (Bendtsen et al., 2014). 
Differences between studies could result from different methods of 
assessing NAD+ content. However, studies obtaining different results have 
used similar methodologies to determine NAD+ levels. For instance, 
commercial kits were used in some studies (Choi et al., 2013; Drew et al., 
2016; Wang et al., 2017; Zhou et al., 2016), while other studies used mass 
spectrometry (Gariani et al., 2016), HPLC (Penke et al., 2015; Yoshino et 
al., 2011), or a cycling assay (Uddin et al., 2017) similar to the assay applied in 
the present study. Thus, results appear not to be associated with a 
particular method for NAD+ detection. 
Differences between observed changes in NAD+  in response to 
dietary interventions could potentially be due to the specific mouse strains 
used and how well glycemic control is maintained. Per- turbed whole body 
glucose metabolism may affect the hepatic NAD+ pool more than obesity. 
For instance, a ~20% decrease in hepatic NAD+ was observed after 20 weeks 
of 60% HFD feeding, but this was further reduced to 50% when these mice 
were treated with streptozotocin to induce diabetes (Trammell et al., 2016). 
We used C57BL6/JBomTac mice that were able to maintain glycemic control 
throughout the study. Interestingly, the C57BL6/JBomTac mice have 
recently been demonstrated to have a deletion in the Y-chromo- some  
that  confers  decreased  fertility  (MacBride  et  al.,  2017). However, 
whether this deletion plays any role in maintaining NAD+ levels in 
C57BL/6JBomTac mice on a HFD has not been investigated. A mutation in 
the Nnt gene in C57BL/6J was demonstrated to contribute to the impaired 
glucose tolerance observed in this strain (Toye et al., 2005). The majority of 
studies demonstrating decreased NAD+ levels in the liver of HFD-fed animals 
have been conducted in C57BL/6J (Gariani et al., 2016; Uddin et al., 2017; 
Zhou et al., 2016). Studies reporting no changes or increases in hepatic NAD+ 
content after  HFD  feeding,  however,  were  performed  in  C57BL/6  mice 
without the Nnt mutation (Drew et al., 2016; Penke et al., 2015; Williams 
et al., 2014). Thus, it is possible that the mutation in Nnt 
contributes to the decrease in NAD+  levels in HFD-fed C57BL/6J 
mice. It should be noted that decreased NAD+ levels in response to a HFD 
are not limited to C57BL/6J mice. Decreased NAD+ levels following HFD 
have been observed in ICR mice (Wang et al., 2017; Zhang et al., 2014) and 
BALB/C mice (Choi et al., 2013). 
  
 
A final source of variation between studies could be time of sacrifice, 
as NAD+ levels and Nampt mRNA levels oscillate (Ramsey et al., 2009). 
However, as most reports do not state the time of sacrifice, it is not possible 
to assess if time of sacrifice is an important factor in this context. 
NAMPT protein abundance in the liver was unaffected by HFD 
consumption in our study. In contrast to NAMPT, NMNAT1 abun- dance 
was slightly increased in HFD-fed mice, and NMNAT3 abundance was 
decreased. Another study reported increased Nmnat1 mRNA levels and 
decreased NMNAT3 protein abundance in the first week of HFD feeding, 
but this was normalized after 3 weeks (Drew et al., 2016). NMNAT1 
levels generally increased with age, which was also the case for NRK1. 
NRK1 is essential in processing NR, but is also important for utilizing NMN 
(Ratajczak 
et al., 2016). The increased abundance of these two enzymes may suggest 
an increased demand for NAD+ with age. PARP1 abun- dance increased 
slightly  with HFD, which was also  previously observed for mRNA levels 
(Drew et al., 2016). On the other hand, none of the investigated sirtuins 
changed in abundance with age 
or diet. Thus, while hepatic knockout of SIRT1 and SIRT6 causes steatosis 
(Kim et al., 2010; Purushotham et al., 2009), HFD- induced hepatic steatosis 
per se does not affect the abundance of these proteins. We cannot rule 
out that endogenous sirtuin ac- tivity is affected, as mice fed a 45% HFD 
for 16 weeks had decreased hepatic SIRT3 activity, but unaltered SIRT3 
abundance (Kendrick et al., 2011). The effects of HDF feeding on hepatic 
SIRT3 abundance is unclear, as another study reported decreased SIRT3 
abundance after HFD feeding (Hirschey et al., 2011). This study also 
reported hepatic hyperacetylation following chronic HFD feeding, which 
was not observed in our study. In contrast, malonyl-lysine band intensity 
was reduced in HFD-fed mice after 
6 weeks, which persisted throughout the experiment. Lysine residues are 
demalonylated by SIRT5 (Du et al., 2011), but SIRT5 abundance was 
unaltered between chow-fed and HFD-fed mice in our study, indicating either 
increased SIRT5 activity or decreased addition of malonyl to lysine targets. 
SIRT5 regulates a range of important processes in the liver, such as the urea 
cycle, ketogen- esis and b-oxidation. Mice fed a 60% HFD for 16 weeks have 
increased malonyl-CoA levels compared to LFD-fed mice (Go et al., 2016), 
which could suggest that malonyl-CoA accumulates, even though altered 
malonyl-CoA levels were not observed in our LCMS analysis. Malonyl-CoA 
is an important metabolite for regulating fatty-acid oxidation and synthesis 
(Saggerson, 2008). A previous study investigated the malonylome by 
proteomic analysis, and found that 72% of the identified malonylated 
proteins were involved in metabolism, especially glucose metabolism (Du 
et al., 2015). It is currently not known how malonylation affects protein 
activity, although site-specific malonylation of fructose bisphos- phate 
aldolase B (ALDOB) decrease the enzymatic activity (Du et al., 2015). 
Decreased protein malonylation may therefore represent an early adaptation 
to a fat-based metabolism. How- ever, the significance of malonylation for 
adapting to HFD-feeding remains  undetermined. 
In conclusion, we find that hepatic lipid accumulation in response to 
prolonged HFD feeding in C57BL/6JBomTac mice does not affect the hepatic 
NAD+ pool or compromise the hepatic NAD+ salvage pathway. While HFD 
causes major changes to whole body metabolism, the liver NAD+ salvage 
system is resilient, even in the presence of macrovesicular steatosis. HFD 
causes minor changes in the abundance of NMNAT1, NMNAT3, PARP1, 
NADP+, and NADPH, but not NAMPT or NAD+. As HFD feeding per se does 
not appear to affect the function of the NAD+ salvage pathway, the 
decreased NAD+ salvage pathway function reported in other studies could 
be mediated by other factors than hepatic lipid accumulation. 
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